Molecular profiling for precision cancer therapies
Top Cited Papers
Open Access
- 14 January 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Genome Medicine
- Vol. 12 (1), 1-19
- https://doi.org/10.1186/s13073-019-0703-1
Abstract
The number of druggable tumor-specific molecular aberrations has grown substantially in the past decade, with a significant survival benefit obtained from biomarker matching therapies in several cancer types. Molecular pathology has therefore become fundamental not only to inform on tumor diagnosis and prognosis but also to drive therapeutic decisions in daily practice. The introduction of next-generation sequencing technologies and the rising number of large-scale tumor molecular profiling programs across institutions worldwide have revolutionized the field of precision oncology. As comprehensive genomic analyses become increasingly available in both clinical and research settings, healthcare professionals are faced with the complex tasks of result interpretation and translation. This review summarizes the current and upcoming approaches to implement precision cancer medicine, highlighting the challenges and potential solutions to facilitate the interpretation and to maximize the clinical utility of molecular profiling results. We describe novel molecular characterization strategies beyond tumor DNA sequencing, such as transcriptomics, immunophenotyping, epigenetic profiling, and single-cell analyses. We also review current and potential applications of liquid biopsies to evaluate blood-based biomarkers, such as circulating tumor cells and circulating nucleic acids. Last, lessons learned from the existing limitations of genotype-derived therapies provide insights into ways to expand precision medicine beyond genomics.Keywords
This publication has 167 references indexed in Scilit:
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase InhibitorsArchives Of Pathology & Laboratory Medicine, 2013
- EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsVirchows Archiv, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancerBMC Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Genome-scale analysis of aberrant DNA methylation in colorectal cancerGenome Research, 2011
- The NIH Roadmap Epigenomics Mapping ConsortiumNature Biotechnology, 2010
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor boardCancer, 2006
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal CancerCancer Research, 2006